p53-based therapeutics for head and neck squamous cell carcinoma
Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 funct...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tassone, Patrick [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole - 2012transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:49 ; year:2013 ; number:8 ; pages:733-737 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.oraloncology.2013.03.447 |
|---|
| Katalog-ID: |
ELV021622116 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV021622116 | ||
| 003 | DE-627 | ||
| 005 | 20230625133928.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2013.03.447 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013002000009.pica |
| 035 | |a (DE-627)ELV021622116 | ||
| 035 | |a (ELSEVIER)S1368-8375(13)00528-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 650 |q VZ |
| 084 | |a 85.03 |2 bkl | ||
| 084 | |a 31.80 |2 bkl | ||
| 084 | |a 54.80 |2 bkl | ||
| 084 | |a 50.03 |2 bkl | ||
| 100 | 1 | |a Tassone, Patrick |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a p53-based therapeutics for head and neck squamous cell carcinoma |
| 264 | 1 | |c 2013transfer abstract | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. | ||
| 520 | |a Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. | ||
| 650 | 7 | |a Anti-cancer therapeutics |2 Elsevier | |
| 650 | 7 | |a Human papillomavirus |2 Elsevier | |
| 650 | 7 | |a Oral cancer |2 Elsevier | |
| 650 | 7 | |a Head and neck cancer |2 Elsevier | |
| 650 | 7 | |a Gene therapy |2 Elsevier | |
| 650 | 7 | |a Tumor suppressor gene |2 Elsevier | |
| 650 | 7 | |a p53 |2 Elsevier | |
| 700 | 1 | |a Old, Matthew |4 oth | |
| 700 | 1 | |a Teknos, Theodoros N. |4 oth | |
| 700 | 1 | |a Pan, Quintin |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |d 2012transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV011194073 |
| 773 | 1 | 8 | |g volume:49 |g year:2013 |g number:8 |g pages:733-737 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.oraloncology.2013.03.447 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 85.03 |j Methoden und Techniken der Betriebswirtschaft |q VZ |
| 936 | b | k | |a 31.80 |j Angewandte Mathematik |q VZ |
| 936 | b | k | |a 54.80 |j Angewandte Informatik |q VZ |
| 936 | b | k | |a 50.03 |j Methoden und Techniken der Ingenieurwissenschaften |q VZ |
| 951 | |a AR | ||
| 952 | |d 49 |j 2013 |e 8 |h 733-737 |g 5 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
p t pt |
|---|---|
| matchkey_str |
tassonepatrickoldmatthewteknostheodorosn:2013----:5bsdhrpuisohaadekqa |
| hierarchy_sort_str |
2013transfer abstract |
| bklnumber |
85.03 31.80 54.80 50.03 |
| publishDate |
2013 |
| allfields |
10.1016/j.oraloncology.2013.03.447 doi GBVA2013002000009.pica (DE-627)ELV021622116 (ELSEVIER)S1368-8375(13)00528-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Tassone, Patrick verfasserin aut p53-based therapeutics for head and neck squamous cell carcinoma 2013transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. Anti-cancer therapeutics Elsevier Human papillomavirus Elsevier Oral cancer Elsevier Head and neck cancer Elsevier Gene therapy Elsevier Tumor suppressor gene Elsevier p53 Elsevier Old, Matthew oth Teknos, Theodoros N. oth Pan, Quintin oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:49 year:2013 number:8 pages:733-737 extent:5 https://doi.org/10.1016/j.oraloncology.2013.03.447 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 49 2013 8 733-737 5 045F 610 |
| spelling |
10.1016/j.oraloncology.2013.03.447 doi GBVA2013002000009.pica (DE-627)ELV021622116 (ELSEVIER)S1368-8375(13)00528-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Tassone, Patrick verfasserin aut p53-based therapeutics for head and neck squamous cell carcinoma 2013transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. Anti-cancer therapeutics Elsevier Human papillomavirus Elsevier Oral cancer Elsevier Head and neck cancer Elsevier Gene therapy Elsevier Tumor suppressor gene Elsevier p53 Elsevier Old, Matthew oth Teknos, Theodoros N. oth Pan, Quintin oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:49 year:2013 number:8 pages:733-737 extent:5 https://doi.org/10.1016/j.oraloncology.2013.03.447 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 49 2013 8 733-737 5 045F 610 |
| allfields_unstemmed |
10.1016/j.oraloncology.2013.03.447 doi GBVA2013002000009.pica (DE-627)ELV021622116 (ELSEVIER)S1368-8375(13)00528-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Tassone, Patrick verfasserin aut p53-based therapeutics for head and neck squamous cell carcinoma 2013transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. Anti-cancer therapeutics Elsevier Human papillomavirus Elsevier Oral cancer Elsevier Head and neck cancer Elsevier Gene therapy Elsevier Tumor suppressor gene Elsevier p53 Elsevier Old, Matthew oth Teknos, Theodoros N. oth Pan, Quintin oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:49 year:2013 number:8 pages:733-737 extent:5 https://doi.org/10.1016/j.oraloncology.2013.03.447 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 49 2013 8 733-737 5 045F 610 |
| allfieldsGer |
10.1016/j.oraloncology.2013.03.447 doi GBVA2013002000009.pica (DE-627)ELV021622116 (ELSEVIER)S1368-8375(13)00528-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Tassone, Patrick verfasserin aut p53-based therapeutics for head and neck squamous cell carcinoma 2013transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. Anti-cancer therapeutics Elsevier Human papillomavirus Elsevier Oral cancer Elsevier Head and neck cancer Elsevier Gene therapy Elsevier Tumor suppressor gene Elsevier p53 Elsevier Old, Matthew oth Teknos, Theodoros N. oth Pan, Quintin oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:49 year:2013 number:8 pages:733-737 extent:5 https://doi.org/10.1016/j.oraloncology.2013.03.447 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 49 2013 8 733-737 5 045F 610 |
| allfieldsSound |
10.1016/j.oraloncology.2013.03.447 doi GBVA2013002000009.pica (DE-627)ELV021622116 (ELSEVIER)S1368-8375(13)00528-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Tassone, Patrick verfasserin aut p53-based therapeutics for head and neck squamous cell carcinoma 2013transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. Anti-cancer therapeutics Elsevier Human papillomavirus Elsevier Oral cancer Elsevier Head and neck cancer Elsevier Gene therapy Elsevier Tumor suppressor gene Elsevier p53 Elsevier Old, Matthew oth Teknos, Theodoros N. oth Pan, Quintin oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:49 year:2013 number:8 pages:733-737 extent:5 https://doi.org/10.1016/j.oraloncology.2013.03.447 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 49 2013 8 733-737 5 045F 610 |
| language |
English |
| source |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:49 year:2013 number:8 pages:733-737 extent:5 |
| sourceStr |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:49 year:2013 number:8 pages:733-737 extent:5 |
| format_phy_str_mv |
Article |
| bklname |
Methoden und Techniken der Betriebswirtschaft Angewandte Mathematik Angewandte Informatik Methoden und Techniken der Ingenieurwissenschaften |
| institution |
findex.gbv.de |
| topic_facet |
Anti-cancer therapeutics Human papillomavirus Oral cancer Head and neck cancer Gene therapy Tumor suppressor gene p53 |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| authorswithroles_txt_mv |
Tassone, Patrick @@aut@@ Old, Matthew @@oth@@ Teknos, Theodoros N. @@oth@@ Pan, Quintin @@oth@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011194073 |
| dewey-sort |
3610 |
| id |
ELV021622116 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV021622116</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625133928.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2013.03.447</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013002000009.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV021622116</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(13)00528-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tassone, Patrick</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">p53-based therapeutics for head and neck squamous cell carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-cancer therapeutics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Human papillomavirus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oral cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gene therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tumor suppressor gene</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">p53</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Old, Matthew</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teknos, Theodoros N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pan, Quintin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:49</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:8</subfield><subfield code="g">pages:733-737</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2013.03.447</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">49</subfield><subfield code="j">2013</subfield><subfield code="e">8</subfield><subfield code="h">733-737</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Tassone, Patrick |
| spellingShingle |
Tassone, Patrick ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Anti-cancer therapeutics Elsevier Human papillomavirus Elsevier Oral cancer Elsevier Head and neck cancer Elsevier Gene therapy Elsevier Tumor suppressor gene Elsevier p53 p53-based therapeutics for head and neck squamous cell carcinoma |
| authorStr |
Tassone, Patrick |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011194073 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 650 - Management & auxiliary services |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl p53-based therapeutics for head and neck squamous cell carcinoma Anti-cancer therapeutics Elsevier Human papillomavirus Elsevier Oral cancer Elsevier Head and neck cancer Elsevier Gene therapy Elsevier Tumor suppressor gene Elsevier p53 Elsevier |
| topic |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Anti-cancer therapeutics Elsevier Human papillomavirus Elsevier Oral cancer Elsevier Head and neck cancer Elsevier Gene therapy Elsevier Tumor suppressor gene Elsevier p53 |
| topic_unstemmed |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Anti-cancer therapeutics Elsevier Human papillomavirus Elsevier Oral cancer Elsevier Head and neck cancer Elsevier Gene therapy Elsevier Tumor suppressor gene Elsevier p53 |
| topic_browse |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Anti-cancer therapeutics Elsevier Human papillomavirus Elsevier Oral cancer Elsevier Head and neck cancer Elsevier Gene therapy Elsevier Tumor suppressor gene Elsevier p53 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m o mo t n t tn tnt q p qp |
| hierarchy_parent_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| hierarchy_parent_id |
ELV011194073 |
| dewey-tens |
610 - Medicine & health 650 - Management & public relations |
| hierarchy_top_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011194073 |
| title |
p53-based therapeutics for head and neck squamous cell carcinoma |
| ctrlnum |
(DE-627)ELV021622116 (ELSEVIER)S1368-8375(13)00528-9 |
| title_full |
p53-based therapeutics for head and neck squamous cell carcinoma |
| author_sort |
Tassone, Patrick |
| journal |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| journalStr |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
733 |
| author_browse |
Tassone, Patrick |
| container_volume |
49 |
| physical |
5 |
| class |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tassone, Patrick |
| doi_str_mv |
10.1016/j.oraloncology.2013.03.447 |
| dewey-full |
610 650 |
| title_sort |
p53-based therapeutics for head and neck squamous cell carcinoma |
| title_auth |
p53-based therapeutics for head and neck squamous cell carcinoma |
| abstract |
Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. |
| abstractGer |
Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. |
| abstract_unstemmed |
Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| container_issue |
8 |
| title_short |
p53-based therapeutics for head and neck squamous cell carcinoma |
| url |
https://doi.org/10.1016/j.oraloncology.2013.03.447 |
| remote_bool |
true |
| author2 |
Old, Matthew Teknos, Theodoros N. Pan, Quintin |
| author2Str |
Old, Matthew Teknos, Theodoros N. Pan, Quintin |
| ppnlink |
ELV011194073 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.oraloncology.2013.03.447 |
| up_date |
2024-07-06T20:06:01.183Z |
| _version_ |
1803861477225922560 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV021622116</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625133928.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2013.03.447</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013002000009.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV021622116</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(13)00528-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tassone, Patrick</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">p53-based therapeutics for head and neck squamous cell carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Inactivation of the tumor suppressor p53 is a pathogenetic event in the development of head and neck squamous cell carcinoma (HNSCC). In the absence of functional wildtype p53, HNSCC cells have increased resistance to standard chemotherapeutics and radiation. Numerous approaches to restore p53 function in cancer cells have been developed over the past several decades. This review article focuses on viral approaches to deliver wildtype p53 to HNSCC cells, a designer virus that selectively eliminates mutant p53 HNSCC cells, and chemical approaches to reactivate p53 function in HNSCC cells. These promising studies provide evidence that p53 therapeutics may prove useful alone or in combination with conventional chemotherapy and/or radiation for the management of HNSCC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-cancer therapeutics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Human papillomavirus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oral cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Gene therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tumor suppressor gene</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">p53</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Old, Matthew</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teknos, Theodoros N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pan, Quintin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:49</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:8</subfield><subfield code="g">pages:733-737</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2013.03.447</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">49</subfield><subfield code="j">2013</subfield><subfield code="e">8</subfield><subfield code="h">733-737</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3974285 |